

Peptomyc Closes €5 Million Equity Financing to Advance OMO-103 Toward the Next Stage of Development

Barcelona, Spain - March 24, 2026

Peptomyc today announced the closing of a €5 million equity financing to advance the next stage of development of OMO-103, the first direct MYC inhibitor with clinical validation. The financing was led by Alta Life Sciences and Aurora Science, with participation from new investors, the EIC Fund, part of the European Innovation Council, and Laudecum, as well as follow-on participation from existing investor, CDTI Innovación, through its SICC Invierte.

The proceeds from the financing will be used to advance OMO-103 toward its next development milestones, including the completion of ongoing clinical studies, continued progress on manufacturing readiness for later-stage development, and ongoing strategic partnering activities. The financing reflects continued support for Peptomyc's progress.

"We are grateful for the support of our investors and for the confidence they have placed in Peptomyc as we advance OMO-103 into later-stage clinical development," said Jesús Martín García, CEO of Peptomyc. "This financing provides us with the resources to execute on our ongoing studies, strengthen our development capabilities, and support ongoing discussions with potential pharmaceutical partners."

Montserrat Vendrell, Partner at Asabys Partners and Board Member at Peptomyc, commented: *"Peptomyc represents an important opportunity in oncology. OMO-103 is the first and only direct MYC inhibitor that has demonstrated a favorable safety profile in clinical trials, with promising signs of biological and clinical activity. MYC is a key oncogene in approximately 70% of cancers, and Peptomyc's ability to target this previously perceived 'undruggable' target opens new therapeutic possibilities. We are excited to continue supporting the team at this important stage of development."*

OMO-103 is the first direct MYC inhibitor with clinical validation, having demonstrated a favorable safety profile, target engagement, and early signs of clinical activity. Peptomyc is currently advancing OMO-103 across three ongoing clinical studies, including a Phase 1b trial in metastatic pancreatic cancer, a Phase 2 trial in osteosarcoma, and a Window-of-Opportunity study in pancreatic cancer.

In parallel, Peptomyc is continuing discussions with potential pharmaceutical partners to explore collaborations aimed at accelerating the development of OMO-103. Together with ongoing clinical execution and manufacturing readiness activities, these discussions are intended to support the company's progress toward the next stage of development for OMO-103.

About Peptomyc

Peptomyc is a Barcelona-based clinical-stage biotechnology company developing therapeutics based on direct MYC inhibition. Founded by leaders in MYC biology, the company is advancing OMO-103, its lead asset and the first direct MYC inhibitor with clinical validation, with the goal of bringing a new therapeutic approach to patients with MYC-driven cancers.

Media Contact

Communications	Núria Gumà, Peptomyc
Email	info@peptomyc.com